kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
2,465
JPY
+95
(+4.01%)
Dec 12, 3:30 pm JST
15.82
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
2,585
Dec 12, 11:59 pm JST
Summary Chart Historical News Financial Result
PER
11.3
PBR
2.74
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
2,375 JPY 15.27 USD
Previous Close Dec 11
2,370 JPY 15.18 USD
High Dec 12, 9:48 am
2,477 JPY 15.91 USD
Low Dec 12, 9:00 am
2,371 JPY 15.24 USD
Volume
1,286,700
Trading Value
3.14B JPY 0.02B USD
VWAP
2438.35 JPY 15.65 USD
Minimum Trading Value
246,500 JPY 1,582 USD
Market Cap
0.14T JPY 0.88B USD
Number of Trades
3,120
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
3,835
1-Year High May 27, 2025
36,454
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 876,600 6,729,500 7.68
Nov 28, 2025 902,600 7,033,000 7.79
Nov 21, 2025 844,700 7,152,100 8.47
Nov 14, 2025 846,000 7,237,700 8.56
Nov 7, 2025 847,700 7,342,900 8.66
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.